家庭会议减少衰弱老年人多重用药的成本效果
COFRAIL整群随机对照试验在德国全科医生与521名居家衰弱多重用药老年人中评估家庭会议式deprescribing的成本效果。干预相关成本为每人391欧元,每100人约增加7次入院、获得2个QALY、额外成本117,681欧元(不含住院费用)。在常用支付意愿阈值下干预具有成本效果的概率为46%,长期成本效果有待评估。
要点
- 干预相关成本为每人391欧元(459美元)。
- 每100人约增加7次入院(95%CI:-12;26),获得2个QALY(95%CI:-1;6)。
- 每获得1个QALY额外成本50,966欧元,支付意愿45,000欧元/QALY时成本效果概率46%。
核心结论
- COFRAIL干预在12个月后主要影响QALY而非入院次数。
- 干预倾向于增加成本和QALY,但在常用支付意愿阈值下较常规照护更不可能具有成本效果。
- 长期成本效果有待评估。
研究设计与样本
- COFRAIL整群随机对照试验,在德国由全科医生参与,纳入521名居家衰弱多重用药老年人。
- 从德国社会保险视角分析成本,采用调整GLM回归估计组间差异,并对插补数据进行分析。
- 通过模拟重抽样绘制 bootstrap 成本-结局配对以展示不确定性,计算给定支付意愿阈值下的成本效果概率,并进行敏感性分析评估稳健性。
主要发现
- 干预相关成本为每人391欧元(459美元)。
- 每100人约增加7次入院(95%CI:-12;26),获得2个QALY(95%CI:-1;6)。
- 每100人额外成本为117,681欧元(95%CI:-28,838;264,201)[138,027美元(95%CI:-33,824;309,880)](不含住院费用),或124,866欧元(95%CI:-12,649;262,380)[146,455美元(95%CI:-14,836;307,745)](含住院费用),与常规照护相比。
- bootstrap显示干预成本更高且入院更多的相对频率为28%-78%,以QALY计为57%-91%。
临床怎么用
- 家庭会议干预增加的成本和QALY幅度较小,在常用支付意愿阈值下成本效果概率不高。
- 临床决策需结合长期成本效果数据及患者偏好综合考量。
局限性
- 研究仅报告12个月结果,长期成本效果未评估。
- 成本和结局的不确定性区间较宽,成本效果概率受支付意愿阈值影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cost-effectiveness of family conferences on deprescribing with joint prioritization of treatment goals in primary care has not been investigated so far. We assessed cost-effectiveness in the cluster-randomized controlled COFRAIL trial conducted with general practitioners and 521 older frail patients with polypharmacy cared for at home in Germany. METHODS: Hospital admissions averted and quality-adjusted life years (QALYs) gained were associated with costs from the German Social Insurance perspective. We applied adjusted GLM regressions with specified distributions to estimate group differences on imputed data, plotted bootstrap cost-outcome pairs by simulated resampling of the study population to illustrate uncertainty and calculate the probability of cost-effectiveness given a willingness-to-pay threshold, and assessed robustness in sensitivity analyses. RESULTS: Intervention-related costs were €391 (US$459) per capita. On 100 people, the COFRAIL intervention had about 7 more hospital admissions (95% CI: -12; 26), 2 QALYs gained (95% CI: -1; 6), and additional costs of €117,681 (95% CI: -28,838; 264,201)/US$138,027 (95% CI: -33,824; 309,880) or €124,866 (95% CI: -12,649; 262,380)/US$146,455 (95% CI: -14,836; 307,745) without or with hospital costs, respectively, compared to usual care. By bootstrapping, we observed the COFRAIL intervention to have higher costs and more hospital admissions with a relative frequency of 28%-78%, or in terms of QALYs 57%-91%. The COFRAIL intervention had additional costs of €50,966 (US$59.778) per QALY gained with a 46% probability of being cost-effective at a willingness to pay of €45,000/QALY (≈US$50,000/QALY). CONCLUSION: The COFRAIL intervention affected QALYs rather than hospital admissions after 12 months. The intervention tended to be associated with higher costs and QALYs but was less likely to be cost-effective than usual care at commonly used willingness-to-pay thresholds. Long-term cost-effectiveness should be assessed.
引用
- Montalbo J, Dintsios CM, Abraham J, et al. Cost-Effectiveness of Family Conferences to Reduce Polypharmacy in Frail Older Adults. J Am Geriatr Soc. 2025. PMID: 40576953. doi:10.1111/jgs.19606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。